KEESHA TYLER: Open Payments
NPI 1174829915 · DOTHAN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,685 in 136 payments from 20 companies in 2025. Trend: 2023 $2,430 · 2024 $2,153 · 2025 $2,685
Food & beverage: $2,651Education: $34
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 26 | $414 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 15 | $334 |
| AstraZeneca Pharmaceuticals LP | 14 | $299 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $298 |
| Amgen Inc. | 14 | $250 |
| GENZYME CORPORATION | 7 | $179 |
| Verona Pharma, Inc. | 9 | $169 |
| Regeneron Healthcare Solutions, Inc. | 8 | $161 |
| Insmed, Inc. | 6 | $140 |
| United Therapeutics Corporation | 5 | $113 |
Products named: TEZSPIRE, DUPIXENT, TRELEGY ELLIPTA, Ohtuvayre, OFEV, Arikayce, GLASSIA, NUCALA.
Industry payments across AL — which companies pay providers there.
